The Community for Open Antimicrobial Drug Discovery (CO-ADD) is a not-for-profit initiative led by academics at The University of Queensland in Brisbane, Australia.
Our goal is to screen compounds from academic research groups from anywhere in the world for free. Submitted compounds are screened at no cost against a key panel of drug-resistant bacterial strains, including E. coli,K. pneumoniae, A. baumannii, P. aeruginosa, S. aureus (MRSA), as well as the fungi C. neoformans and C. albicans.
We aim to help researchers around the world to find new, diverse compounds to combat the superbug crisis.
The Community for Open Antimicrobial Drug Discovery Chemistry Prize will recognise academic researchers who focus on producing synthetic compounds or isolating pure natural compounds in any field of research, such as medicine, veterinary, and/or agriculture.
Four prizes will be awarded based on the diversity of compounds chemists can produce. The compounds can be any organic molecule, and do not have to have been designed with antimicrobial activity in mind. Prize winners must send these compounds to CO-ADD for free antimicrobial screening.
The judging panel will select an overall winner (1st prize) who will receive a cash component of US$2500. Our 2nd and 3rd prizewinners will each be awarded US$1000. The people’s choice category winner, as voted by the public, will also be awarded US$1000. Cash prizes must be used towards the costs of sample collection and/or preparation for CO-ADD antimicrobial screening.
Academic researchers and students from any institute, university or educational institution in the world who have compounds they can make available for CO-ADD antimicrobial screening.
How to enter?
In your application please include:
1.Summary of your research
Briefly tell us about you and your research (150 words max)
Under the 'Description' section of the application:
2.Tell us about your compounds
How chemically diverse are they? How many compounds would you like to send us? Do you have the capabilities to prepare them for CO-ADD antimicrobial screening (1mg or 50 uL at 10mg/uL)? (400 words max)
3.Why do you want to help CO-ADD contribute to the fight against superbugs?
(150 words max)
Add any additional information can be added in the 'Additional Information' part of the application.
If you would like to also apply for the people’s choice award, in your application upload a short 60 second video with your answer to the question: "How can chemistry fight the war on superbugs and help find the next antibiotic?"
All applications will be judged by our expert panel, including:
Dr Mark Blaskovich, The University of Queensland, CO-ADD (Australia)
Dr Siouxsie Wiles,The University of Auckland (New Zealand)
Prof Mark Moloney, University of Oxford, Department of Chemistry (UK)
A/Prof GO Mei Lin – National University of Singapore (Singapore)
Winners will be announced on February 2, 2016. Only one submission can be made per person. The judging panel’s decision will be final and no further correspondence will be entered in to.
People's Choice Award
Along with the 3 judged awards, we will be awarding a 'People's Choice Award' to the value of US$1000.
What winners need to do?
The four winners are required to:
Prepare and send their compounds to CO-ADD’s laboratories in Brisbane, Australia within 8 weeks of receiving their prize money
Make themselves available for promotional opportunities directly associated with the CO-ADD Chemistry Prize (press release)
Details of the Prize Judging Panel
Dr Mark BLASKOVICH – The University of Queensland (Australia)
Dr. Mark Blaskovich is a senior research officer at The University of Queensland’s Institute for Molecular Bioscience with extensive medicinal chemistry expertise and over 15 years of industrial drug development experience. As Chief Operating Officer at Mimetica (Australia), he managed the drug discovery and development program for melanocortin-5 receptor antagonists leading to a compound currently in Phase II human trials. In his role at CEPTYR (Seattle) he led a multidisciplinary team that developed a preclinical candidate for protein tyrosine phosphatase 1B, while at Molecumetics (Seattle) he headed a $2m/yr industrial collaboration on peptidomimetic compounds targeting proteases and GPCRs. Since 2015, Mark is a program coordinator for hit validation and chemistry for The Community for Open Antimicrobial Drug Discovery (CO-ADD). He has published over thirty articles and patents, and is sole author of 'The Handbook on Syntheses of Amino Acids'.
Dr Siouxsie WILES – The University of Auckland (New Zealand)
Dr Siouxsie Wiles describes herself as a microbiologist and bioluminescence enthusiast. Head of the Bioluminescent Superbugs Lab at the University of Auckland, Siouxsie combines her twin passions to understand infectious diseases. In a nutshell, Siouxsie and her team make nasty bacteria glow in the dark. Siouxsie is also interested in demystifying science for the general public, and raising awareness of the growing threat of antibiotic-resistant superbugs. She is a blogger and podcaster, as well as being a regular science commentator for Radio NZ’s Nine to Noon programme. Siouxsie has also teamed up with Australian graphic artist Luke Harris, to make short animations describing nature’s amazing glowing creatures and the many uses of bioluminescence in science.
Dr Siouxsie Wiles studied medical microbiology at the University of Edinburgh, followed by a PhD in microbiology at the Oxford Centre for Ecology and Hydrology. She then moved to Imperial College London where her research won her the inaugural National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) 3Rs prize. In 2009, Siouxsie was awarded a Sir Charles Hercus Fellowship from the Health Research Council of New Zealand and relocated to the University of Auckland.
Prof Mark MOLONEY – University of Oxford (United Kingdom)
Prof Moloney was appointed as a University lecturer and Tutorial Fellow in Organic Chemistry at Oxford University and St Peter’s College in 1990, where he is currently EP Abraham Fellow and Professor of Chemistry. Having begun his career working in synthetic methodology using main group metal-mediated reactions and the synthesis of functionalised, saturated enantiopure nitrogen heterocycles, more recently his research interests have come to include the development of new generations of antibacterials, inspired by tetramate-containing natural products which are themselves antibacterial. This work has clearly shown the potential of such structures for the identification of highly novel bioactive systems and in particular of wholly new classes of antibacterial agents with promising bactericidal activity. Another area of focus has involved the application of reactive carbene chemistry for the surface functionalisation of synthetic and natural polymers; this novel approach has allowed the modification of a wide range of polymers including polyalkanes, polyesters, polyamides with surface colour, hydrophilicity, photochromic, metal chelating, protein and cell adhesion, biocidal and drug delivery activities, which is achieved without compromise of bulk material properties. Commercialisation of chemistry arising from this research by means of a spin-out company has led to innovation in adhesive technologies relevant to the automotive, marine and aeronautical sectors. A current area of interest is the preparation of drug delivery devices, and particularly of antibacterial materials. This has resulted in the publication of nearly 180 papers in the primary, monograph, patent and review literature, and numerous national and international lectures and posters at academic, industrial and conference locations. Mark retains a strong interest in chemical education, and has published 4 textbooks, one of which has been translated into multiple languages.
A/Prof Mei Lin GO – National University of Singapore (Singapore)
My research interests are in the area of designing and synthesizing novel compounds with the aim of establishing structure-property correlations and understanding modes of action by biochemical and pharmacological approaches. Department of Pharmacy, Faculty of Science.
What is CO-ADD?
The Community for Open Antimicrobial Drug Discovery (CO-ADD) is a not-for-profit initiative launched in March 2015 that reachs out to chemists in academia and research organisations who may have compounds ‘sitting on shelves’ that were not designed as antibiotics and would not otherwise be screened for antimicrobial activity.
Our mission is to find new, diverse compounds to combat the superbug crisis.
CO-ADD screens compound libraries at no cost against a key panel of drug-resistant bacterial strains, including E. coli, K. pneumoniae, A. baumannii, P. aeruginosa, S. aureus (MRSA), as well as the fungi C. neoformans and C. albicans.
“Pharmaceutical companies are finding it harder and harder to find new drugs. This is partly because everyone’s screening the same type of compounds. We’ve got to start to think of more creative approaches.” — CO-ADD Director Professor Matt Cooper.
This is why the CO-ADD Chemistry Prize focuses on chemical diversity within compound collections.
Academics around the world generate thousands of new compounds every day, but many of these are never considered or investigated as drug candidates.
Professor Cooper says that potentially there are up to 55,000 antibiotics waiting to be discovered in the collective chemistry universe, but they’ve never been screened against key pathogens.
With the CO-ADD Chemistry Prize, we want to encourage chemists around the world to contribute compounds to CO-ADD and to join the community in the fight against superbugs by contributing to the sample collection and preparation costs.
What can the CO-ADD Chemistry Prize be used on?
The overall winner will receive a cash component of US$2500. The 2nd and 3rd prizewinners will each receive US$1000. The people’s choice category winner, as voted by the public, will receive US$1000.
The funds will be transferred to the winner’s affiliated research organisation, which will be responsible for distributing the research funds to the winner.
The funds must be used towards the costs of sample collection and/or preparation for CO-ADD antimicrobial screening (research stipend or supplies).
I want to send compounds to CO-ADD without entering the prize. What should I do?
The easiest way is to use your phone, or to contact your university or organisation's media department who can help in producing and creating your research video. The panel will be judging on the strength of your content and ideas, and not on video production skills. Please see the Thinkable guidelines on how to create an engaging research video.
Who can I contact if I need additional information?
Mathilde Desselle, Marketing and Outreach Manager, The Community for Open Antimicrobial Drug Discovery.
Entrants consent to Thinkable and CO-ADD using their name, likeness, image and/or voice (including photograph, film and/or recording of the same) in any media for an unlimited period without remuneration for the purpose of promoting this Prize (including any outcome), and promoting the Thinkable Platform.
Thinkable reserves the right, at any time, to verify the validity of entries and entrants (including an entrant’s identity, age and organization affiliation) and reserves the right, in its sole discretion, to disqualify any individual who Thinkable has reason to believe has breached any of these rules, tampered with the entry process or engaged in any unlawful or other improper misconduct calculated to jeopardise fair and proper conduct of the Prize. Errors and omissions may be accepted at Thinkable’s discretion. Failure by Thinkable to enforce any of its rights at any stage does not constitute a waiver of those rights. Thinkable’s legal rights to recover damages or other compensation from such an offender are reserved.
If this Prize is interfered with in any way or is not capable of being conducted as reasonably anticipated due to any reason beyond the reasonable control of Thinkable, including but not limited to technical difficulties, unauthorised intervention or fraud, Thinkable reserves the right, in its sole discretion, to the fullest extent permitted by law: (a) to disqualify any entrant; or (b) subject to any written directions from a regulatory authority, to modify, suspend, terminate or cancel the Prize, as appropriate.
Nothing in these Terms and Conditions limits, excludes or modifies or purports to limit, exclude or modify the statutory consumer guarantees as provided under the Competition and Consumer Act, as well as any other implied warranties under the ASIC Act or similar consumer protection laws in the States and Territories of Australia (“Non-Excludable Guarantees”). Except for any liability that cannot by law be excluded, including the Non-Excludable Guarantees, Thinkable (including its respective officers, employees and agents) excludes all liability (including negligence), for any personal injury; or any loss or damage (including loss of opportunity); whether direct, indirect, special or consequential, arising in any way out of the Prize.
Except for any liability that cannot by law be excluded, including the Non-Excludable Guarantees, Thinkable (including its respective officers, employees and agents) is not responsible for and excludes all liability (including negligence), for any personal injury; or any loss or damage (including loss of opportunity); whether direct, indirect, special or consequential, arising in any way out of: (a) any technical difficulties or equipment malfunction (whether or not under Thinkable’s control); (b) any theft, unauthorised access or third party interference; (c) any entry or Prize claim that is late, lost, altered, damaged or misdirected (whether or not after their receipt by Thinkable) due to any reason beyond the reasonable control of Thinkable; (d) any variation in Prize value incurred by the entrants research organisation; (e) any tax liability incurred by a winner or entrant; or (f) use of and participation in the competition.
The judging panel will select these winners
People's Choice Award
The winner will be awarded based on an open vote from the public